PMCPA Case
| Case | AUTH/2756/5/15 |
| Parties | Anonymous employee v Merck Serono |
| Issue | Call rates / contact-rate targets and certification of field briefings |
| Product referenced | Rebif (interferon beta-1a) |
| Complaint received | 7 May 2015 |
| Case completed | 24 July 2015 |
| Applicable Code year | 2015 |
| Breach clauses | 15.2, 15.4, 15.9 |
| Sanctions | Undertaking received; Additional sanctions: Not stated |
| Appeal | No appeal |
| Field force context | 8 neurology KAMs; ~50–60 MS specialists per territory; March 2015 had 22 working days (Panel calculation: 6 contacts/day ≈ 132 contacts/month) |
Download the full case report (PDF)
Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory
Got a question about this case?
Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.
⭐ Business Intelligence Access
See the full compliance picture for every pharma company
291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.
One real case. One key lesson. Every week — free.